Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 3/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | COASY | Q13057 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743169 | 0.90 | CTSA (0.39) | CTSASOS1COASYPDE2APTGFR | |
| SCHEMBL30645020 | 0.90 | CTSA (0.39) | CTSASOS1COASYPDE2APTGFR | |
| SCHEMBL20743906 | 0.89 | SOS1 (0.44) | CTSASOS1HDAC1HDAC6HDAC5 | |
| SCHEMBL19283565 | 0.88 | GRIN1 (0.40) | CTSASOS1PTGFR | |
| SCHEMBL20744591 | 0.86 | SOS1 (0.40) | CTSASOS1KDRTEKHDAC1 | |
| SCHEMBL20743152 | 0.84 | HDAC1 (0.37) | CTSASOS1HDAC1HDAC6HDAC5 | |
| SCHEMBL20762429 | 0.83 | CCNT1 (0.35) | CTSASOS1COASYPDE2APTGFR | |
| SCHEMBL19283637 | 0.82 | ITGA5 (0.47) | KDRTEKRAF1BRAF | |
| SCHEMBL20743101 | 0.77 | SOS1 (0.46) | CTSASOS1HDAC1HDAC6HDAC5 | |
| SCHEMBL30645115 | 0.77 | SOS1 (0.46) | CTSASOS1HDAC1HDAC6HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | CTSA 2301/4885SOS1 3161/4885KDR 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.